- Home
- PMN vs LSTA Comparison
PMN vs LSTA Comparison
Compare PMN & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMN
- LSTA
- Stock Information
- Founded
- PMN 2004
- LSTA 1980
- Country
- PMN Canada
- LSTA United States
- Employees
- PMN N/A
- LSTA N/A
- Industry
- PMN Pharmaceuticals and Biotechnology
- LSTA Misc Health and Biotechnology Services
- Sector
- PMN Health Care
- LSTA Health Care
- Exchange
- PMN Nasdaq
- LSTA Nasdaq
- Market Cap
- PMN 23.5M
- LSTA 20.9M
- IPO Year
- PMN N/A
- LSTA N/A
- Fundamental
- Price
- PMN $0.44
- LSTA $1.96
- Analyst Decision
- PMN Strong Buy
- LSTA Strong Buy
- Analyst Count
- PMN 3
- LSTA 2
- Target Price
- PMN $4.00
- LSTA $23.50
- AVG Volume (30 Days)
- PMN 483.7K
- LSTA 146.9K
- Earning Date
- PMN 11-12-2025
- LSTA 11-06-2025
- Dividend Yield
- PMN N/A
- LSTA N/A
- EPS Growth
- PMN N/A
- LSTA N/A
- EPS
- PMN N/A
- LSTA N/A
- Revenue
- PMN N/A
- LSTA $1,070,000.00
- Revenue This Year
- PMN N/A
- LSTA N/A
- Revenue Next Year
- PMN N/A
- LSTA N/A
- P/E Ratio
- PMN N/A
- LSTA N/A
- Revenue Growth
- PMN N/A
- LSTA N/A
- 52 Week Low
- PMN $0.35
- LSTA $1.85
- 52 Week High
- PMN $1.59
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- PMN 51.56
- LSTA 34.03
- Support Level
- PMN $0.36
- LSTA $1.92
- Resistance Level
- PMN $0.45
- LSTA $2.13
- Average True Range (ATR)
- PMN 0.04
- LSTA 0.19
- MACD
- PMN 0.00
- LSTA -0.03
- Stochastic Oscillator
- PMN 69.31
- LSTA 22.70
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.